Fractional CO2 laser, platelet rich plasma and narrow band ultraviolet B in the treatment of Vitiligo (A randomized clinical trial)

Lasers Med Sci. 2021 Sep;36(7):1479-1486. doi: 10.1007/s10103-020-03195-9. Epub 2020 Nov 25.

Abstract

Vitiligo is a chronic acquired disease. Various therapeutic strategies are available but with variable degrees of success. Fractional CO2 laser is claimed to be effective in the treatment of refractory non-segmental vitiligo. Platelet-rich plasma may help in stimulation of the proliferation of melanocytes and repigmentation within vitiliginous patches.Our aim was to evaluate and compare the efficacy and safety of fractional CO2 laser, PRP, and NB-UVB either alone or in combination in the treatment of vitiligo. This self-controlled randomized clinical trial included 20 patients with at least 6 patches of vitiligo (VIDA score 1 and 0). Each patch was randomly assigned to receive either, fractional CO2 laser, PRP, combined fractional CO2 with PRP, combined fractional CO2 with NB-UVB, combined fractional CO2 with PRP and NB-UVB or left as a control. There was a statistically significant improvement in all treatment groups on comparing the surface area of vitiligo patches before and after treatment. However on comparing the percentage of reduction in surface area in different treatment groups, there was no statistically significant difference (P = 0.122). Fr: CO2 laser and PRP may be adjuvant therapeutic options to NB-UVB especially in the treatment of refractory cases of non-segmental vitiligo.

Keywords: Fractional; Laser; Plasma; Platelet; Rich; Vitiligo.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Combined Modality Therapy
  • Humans
  • Lasers, Gas* / therapeutic use
  • Platelet-Rich Plasma*
  • Treatment Outcome
  • Ultraviolet Therapy*
  • Vitiligo* / radiotherapy